Clinical Trial

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Protocol Amendment History 5 changes
notable Trial sites expanded: 118 -> 121 locations 2026-08-08
notable Trial sites expanded: 113 -> 118 locations 2026-07-25
notable Trial sites expanded: 109 -> 115 locations 2026-06-13
notable Trial sites expanded: 106 -> 109 locations 2026-05-30
notable Trial sites reduced: 105 -> 102 locations 2026-04-04
Trial Details
NCT Number NCT04976322
Lead Sponsor UCB Biopharma SRL
Conditions Systemic Lupus Erythematosus
Enrollment 760 participants
Start Date 2021-07-27
Primary Completion 2030-08-07 (estimated)
Study Completion 2030-08-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-07